MX2022014550A - Ligandos de péptidos bicíclicos específicos para nectina-4 y usos de los mismos. - Google Patents
Ligandos de péptidos bicíclicos específicos para nectina-4 y usos de los mismos.Info
- Publication number
- MX2022014550A MX2022014550A MX2022014550A MX2022014550A MX2022014550A MX 2022014550 A MX2022014550 A MX 2022014550A MX 2022014550 A MX2022014550 A MX 2022014550A MX 2022014550 A MX2022014550 A MX 2022014550A MX 2022014550 A MX2022014550 A MX 2022014550A
- Authority
- MX
- Mexico
- Prior art keywords
- nectin
- peptide ligands
- ligands specific
- bicyclic peptide
- pharmaceutical composition
- Prior art date
Links
- 102100035486 Nectin-4 Human genes 0.000 title 1
- 101710043865 Nectin-4 Proteins 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 208000037844 advanced solid tumor Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 239000002596 immunotoxin Substances 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 229960003301 nivolumab Drugs 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063027536P | 2020-05-20 | 2020-05-20 | |
| PCT/GB2021/051220 WO2021234391A1 (en) | 2020-05-20 | 2021-05-20 | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014550A true MX2022014550A (es) | 2023-03-02 |
Family
ID=76532225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014550A MX2022014550A (es) | 2020-05-20 | 2021-05-20 | Ligandos de péptidos bicíclicos específicos para nectina-4 y usos de los mismos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181749A1 (enExample) |
| EP (1) | EP4153240A1 (enExample) |
| JP (1) | JP2023526451A (enExample) |
| KR (1) | KR20230037502A (enExample) |
| CN (1) | CN115697417A (enExample) |
| AU (1) | AU2021276616A1 (enExample) |
| CA (1) | CA3179152A1 (enExample) |
| IL (1) | IL298382A (enExample) |
| MX (1) | MX2022014550A (enExample) |
| WO (1) | WO2021234391A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ731185A (en) | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| CA3091775A1 (en) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CN116348476A (zh) | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
| EP4719481A1 (en) * | 2023-06-01 | 2026-04-08 | BicycleTx Limited | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
| WO2024248859A1 (en) * | 2023-06-01 | 2024-12-05 | Bicycletx Limited | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
| CN117003830A (zh) * | 2023-08-04 | 2023-11-07 | 湖南中晟全肽生化有限公司 | 靶向Nectin-4的多肽及其用途 |
| EP4777136A1 (en) * | 2023-09-13 | 2026-07-22 | BicycleTx Limited | Bicyclic peptide ligands specific for nectin-4 and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ267796A3 (cs) * | 1996-09-12 | 1998-04-15 | Galena A.S. | Léčivé přípravky, zejména pro vnitřní aplikaci, ve formě samomikroemulgujících terapeutických systémů |
| US8329188B2 (en) * | 2008-11-12 | 2012-12-11 | Theraclone Sciences, Inc. | Human M2e peptide immunogens |
| RS64268B1 (sr) * | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| JP2018503595A (ja) * | 2014-09-24 | 2018-02-08 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその製剤 |
| EP3677589B1 (en) * | 2017-08-31 | 2025-11-26 | Daiichi Sankyo Company, Limited | Improved method for producing antibody-drug conjugate |
| TWI825046B (zh) * | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| US11180531B2 (en) * | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| WO2020178574A1 (en) * | 2019-03-04 | 2020-09-10 | Bicyclerd Limited | Synthesis of bicycle toxin conjugates, and intermediates thereof |
| MX2021012994A (es) * | 2019-04-24 | 2022-03-04 | Janssen Pharmaceuticals Inc | Administracion heterologa de vacunas tau. |
| CN113527486B (zh) * | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| KR20230060509A (ko) * | 2020-09-04 | 2023-05-04 | 노바록 바이오테라퓨틱스 리미티드 | 넥틴-4 항체 및 이의 용도 |
-
2021
- 2021-05-20 AU AU2021276616A patent/AU2021276616A1/en active Pending
- 2021-05-20 KR KR1020227044522A patent/KR20230037502A/ko active Pending
- 2021-05-20 MX MX2022014550A patent/MX2022014550A/es unknown
- 2021-05-20 US US17/926,454 patent/US20230181749A1/en active Pending
- 2021-05-20 JP JP2022570573A patent/JP2023526451A/ja active Pending
- 2021-05-20 EP EP21733852.4A patent/EP4153240A1/en active Pending
- 2021-05-20 CA CA3179152A patent/CA3179152A1/en active Pending
- 2021-05-20 CN CN202180043142.4A patent/CN115697417A/zh active Pending
- 2021-05-20 IL IL298382A patent/IL298382A/en unknown
- 2021-05-20 WO PCT/GB2021/051220 patent/WO2021234391A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3179152A1 (en) | 2021-11-25 |
| JP2023526451A (ja) | 2023-06-21 |
| KR20230037502A (ko) | 2023-03-16 |
| CN115697417A (zh) | 2023-02-03 |
| EP4153240A1 (en) | 2023-03-29 |
| US20230181749A1 (en) | 2023-06-15 |
| AU2021276616A1 (en) | 2023-01-05 |
| WO2021234391A1 (en) | 2021-11-25 |
| IL298382A (en) | 2023-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005855A (es) | Procedimientos para tratar el cancer. | |
| MX2023001588A (es) | Conjugados biciclo específicos para nectina-4 y usos de estos. | |
| MX2022006001A (es) | Ligandos de peptidos biciclicos especificos para el receptor 2 tipo a de efrina (epha2) y usos de los mismos. | |
| MXPA03010121A (es) | Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales. | |
| MX2022014332A (es) | Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo. | |
| WO2020126620A3 (en) | Improved antibody-oligonucleotide conjugate | |
| PL323450A1 (en) | Application of flavoliganes in production of dugs exhibiting antiproliferation effects in uterus, ovarium and mammary gland | |
| EP1594542A4 (en) | ANTI-CD70 ANTIBODY MEDICAMENT CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES | |
| IL300151A (en) | Combinations for cancer treatment | |
| AU2016293674B2 (en) | A novel approach for treatment of cancer using immunomodulation | |
| NZ592039A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| HRP20151172T1 (hr) | Sastavi i postupci za dijagnosticiranje i lijeäśenje raka | |
| NZ602675A (en) | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| WO2006044643A3 (en) | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders | |
| JP2019520426A5 (enExample) | ||
| IL162141A0 (en) | Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemoterapy | |
| JP2024533067A5 (enExample) | ||
| ZA202210640B (en) | Deuterated oxophenylarsine compound and use thereof | |
| WO2023278897A9 (en) | Compositions and methods for treating cancers | |
| PL363926A1 (en) | Antitumor therapy comprising distamycin derivatives | |
| IL101675A0 (en) | Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors | |
| WO2003072061A3 (en) | Methods and compositions for treating gastrointestinal toxicity induced by cytoablative therapy | |
| MX2025010543A (es) | Composiciones que comprenden 5-metoxi-2-aminoindan para el tratamiento de la depresion | |
| WO2023001283A9 (zh) | 用于治疗胃癌和/或食管胃结合部癌的联用药物 |